Therapeutic strategies targeting IRS stability (e.g., kinase inhibitors), Foxo1 activity, or mitochondrial biogenesis may restore metabolic plasticity and mitigate disease progression, highlighting the interplay between insulin signaling fidelity and cardiac resilience in diabetes (54). Here, INS is linked to diabetes mellitus.